Dana Farber Cancer Institute StudyCoordinator:CAUY922A2101

Boston, Massachusetts 02115

0 studies enrolling now · 1 studies all time

What they study most

Breast Cancer, Hematologic Neoplasms

Studies at this site

• Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients — Completed